OmniAb, Inc.
Matt Foehr has a diverse work experience spanning various roles and companies in the pharmaceutical industry. Matt is currently the Chief Executive Officer at OmniAb, Inc. since November 2022. Prior to that, they served as a Board Member at Viking Therapeutics from May 2014 onwards. From April 2011 to October 2022, they held the position of President and Chief Operating Officer at Ligand Pharmaceuticals. Matt was also a Board Member at Ritter Pharmaceuticals, Inc. from February 2015 to May 2020. Before that, they held several leadership roles at Stiefel, a GSK company, including Vice President and Head of Consumer Dermatology R&D from January 2010 to April 2011. Earlier in their career, they held senior positions at Stiefel Laboratories and Connetics Corporation in various areas such as global R&D operations, product development, supply chain technical services, and manufacturing.
Matt Foehr attended Santa Clara University from 1990 to 1994, but it is not known what degree or field of study they pursued during this time.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.